Targeted Delivery of Liposomal Ribociclib to Slc7a5 Transporters in Breast Cancer Cells Publisher Pubmed

Summary: Scientists report targeted liposomes improve Ribociclib’s cancer-killing power in breast cancer cells. #CancerResearch #DrugDelivery

Afsharzadeh M¹ ; Varshosaz J¹ ; Mirian M² ; Hasanzadeh F³
Source: Investigational New Drugs Published:2024

Abstract

This study aimed to prepare SLC7A5 transporters targeted liposomes of Ribociclib (RB) by stear(o)yl conjugation of Phe, Asp, Glu amino acids to liposomes as targeting moieties. The liposomes were optimized for their formulations. Cell analysis on two cell lines of MCF-7 and NIH-3T3 were done including; cell viability test by MTT assay, cellular uptake, and cell cycle arrest by flow cytometry. The optimal liposomes showed the particle size of 123.6 ± 1.3 nm, drug loading efficiency and release efficiency of 83.87% ± 1.33% and 60.55% ± 0.46%, respectively. The RB loaded liposomes showed no hemolysis activity. Targeted liposomes increased cytotoxicity on MCF-7 cells more significantly than NIH-3T3 cells. Cell flow cytometry indicated that targeted liposomes uptake was superior to plain (non-targted) liposomes and free drug. Free drug and RB-loaded liposomes interrupted cell cycle in G1. However, amino acid-targeted liposomes arrested cells more than the free drug at this stage. Targeted liposomes reduced cell cycle with more interruption in the G2/M phase compared to the negative control. Graphical abstract: (Figure presented.). © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023.